Form 4: Regeneron's CEO Leonard Schleifer Executes Stock Sale Under 10b5-1 Plan

Regeneron's CEO, Leonard Schleifer, sold 787 shares of company stock at an average price of $1,015.02 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• On June 6, 2024, Leonard S. Schleifer, the Bd. Co-Chair, President & CEO of Regeneron Pharmaceuticals, Inc., sold 787 shares of Regeneron's common stock.
• The sale was executed under a pre-arranged trading plan (Rule 10b5-1(c)) adopted on February 5, 2024.
• The shares were sold at a volume-weighted average price of $1,015.02, with individual prices ranging from $1,015.00 to $1,015.25.
• Following the transaction, Schleifer directly owns 466,877 shares of common stock.
• Schleifer also indirectly owns 157,552 shares through a 2023 GRAT, and 5,932 shares through a 401(k) plan.
• Additionally, Schleifer indirectly owns 64,198 shares by trust.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of a stock sale by the CEO under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment, as it's a standard financial transaction.

Industry Context

Executive stock sales are a common occurrence, especially when executed under pre-arranged trading plans like Rule 10b5-1. These plans allow insiders to sell shares at predetermined times and prices, avoiding accusations of insider trading. The market typically views these sales based on the overall volume and context, such as company performance and industry trends.

Comparison to Industry Standards

• Executive stock sales are common in the pharmaceutical industry.
• Companies like Amgen, Gilead, and Pfizer often see similar transactions by their executives.
• The use of 10b5-1 plans is a standard practice to ensure compliance with insider trading regulations.
• The volume of shares sold by Schleifer is relatively small compared to the total outstanding shares of Regeneron.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, depending on market perception.
• The transaction does not directly affect employees, customers, suppliers, or creditors.

Key Dates